Evidence map›Paper›PMID 28614387›Full record

ArticlePLoS pathogens2017

Global sensing of the antigenic structure of herpes simplex virus gD using high-throughput array-based SPR imaging.

Tina M Cairns, Noah T Ditto, Huan Lou, Benjamin D Brooks, Doina Atanasiu, Roselyn J Eisenberg, Gary H Cohen

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Moving beyond Titers.Vaccines · 2022
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Entry of Alphaherpesviruses.Current issues in molecular biology · 2021
    Review
  13. Article
  14. Article
  15. Vaccines to prevent genital herpes.Translational research : the journal of laboratory and clinical medicine · 2020
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Tina M CairnsDepartment of Microbiology, School of Dental Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.ORCID http://orcid.org/0000-0002-6112-6964
Noah T DittoWasatch Microfluidics, Salt Lake City, Utah, United States of America.
Huan LouDepartment of Microbiology, School of Dental Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Benjamin D BrooksWasatch Microfluidics, Salt Lake City, Utah, United States of America.
Doina AtanasiuDepartment of Microbiology, School of Dental Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Roselyn J EisenbergDepartment of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Gary H CohenDepartment of Microbiology, School of Dental Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
University of Pennsylvania · USCarterra (United States) · US

Funding

Studies of Herpes Simplex Virus GlycoproteinsR37AI018289 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI COHEN, GARY H · 2005 to 2014
$3.9M
STUDIES OF HERPES SIMPLEX VIRUS GLYCOPROTEINSR01AI018289 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI COHEN, GARY H · 1985 to 2019
$3.8M
Improving vaccine development through high-throughput immunogenicity screening.R44AI127039 · NIAID · CARTERRA, INC. · PI BROOKS, BENJAMIN DELBERT, COHEN, GARY H · 2016 to 2017
$1.5M
High-throughput, multiplexed characterization and modeling of antibody:antigen binding, with application to HSVR43AI132075 · NIAID · CARTERRA, INC. · PI BAILEY-KELLOGG, CHRIS, BROOKS, BENJAMIN DELBERT · 2017 to 2017
$300k
NIAID NIH HHS R01 AI018289NIAID NIH HHS R37 AI018289NIAID NIH HHS R43 AI132075NIAID NIH HHS R44 AI127039
6 · The paper itself

Abstract

While HSV-2 typically causes genital lesions, HSV-1 is increasingly the cause of genital herpes. In addition, neonatal HSV infections are associated with a high rate of mortality and HSV-2 may increase the risk for HIV or Zika infections, reinforcing the need to develop an effective vaccine. In the GSK Herpevac trial, doubly sero-negative women were vaccinated with a truncated form of gD2 [gD2(284t)], then examined for anti-gD serum titers and clinical manifestations of disease. Surprisingly, few vaccinees were protected against genital HSV-2 but 86% were protected from genital HSV-1. These observations suggest that subtle differences in gD structure might influence a protective response. To better understand the antigenic structure of gD and how it impacts a protective response, we previously utilized several key anti-gD monoclonal antibodies (mAbs) to dissect epitopes in vaccinee sera. Several correlations were observed but the methodology limited the number of sera and mAbs that could be tested. Here, we used array-based surface plasmon imaging (SPRi) to simultaneously measure a larger number of protein-protein interactions. We carried out cross-competition or "epitope binning" studies with 39 anti-gD mAbs and four soluble forms of gD, including a form [gD2(285t)] that resembles the Herpevac antigen. The results from these experiments allowed us to organize the mAbs into four epitope communities. Notably, relationships within and between communities differed depending on the form of gD, and off-rate analysis suggested differences in mAb-gD avidity depending on the gD serotype and length. Together, these results show that gD1 and gD2 differ in their structural topography. Consistent with the Herpevac results, several mAbs that bind both gD1 and gD2 neutralize only HSV-1. Thus, this technology provides new insights into the antigenic structure of gD and provides a rationale as to how vaccination with a gD2 subunit may lead to protection from HSV-1 infection.

Indexed as

AnimalsAntibodies, NeutralizingAntibodies, ViralAntigens, ViralHerpes SimplexHerpesvirus 1, HumanHerpesvirus 2, HumanHerpesvirus VaccinesHigh-Throughput Screening AssaysHumansSurface Plasmon ResonanceViral Envelope ProteinsAntibodies, NeutralizingAntibodies, ViralAntigens, Viralglycoprotein D, Human herpesvirus 1Herpesvirus VaccinesViral Envelope Proteins

Identifiers

PMID28614387
PMCPMC5484518
OpenAlexW2624911194

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.